ScreenerHero

KTTA Pasithea Therapeutics Corp.

NAS · US · Healthcare · Biotechnology · pasithea.com
0.4434USD-0.81%Mkt Cap: 14.82M $P/E: —

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead produc…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap14.82M USD
Enterprise Value-30.76M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-20.43M USD
Revenue/Share—
Last Price0.4434 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.97
PEG—
EV/EBITDA1.61
EV/Revenue—
P/S—
P/B0.30
EPS (TTM)-1.56
EPS (Forward)-0.46
52W Range
0.28109% of range2.060
52W High2.060 USD
52W Low0.2810 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-36.99%
ROA-33.91%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-82.11%
Net Debt-45.66M USD
Net Debt/EBITDA2.39
Balance Sheet
Debt/Equity—
Current Ratio26.25
Quick Ratio24.84
Book Value/Sh1.49 USD
Cash/Share1.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJan 2, 2024
Analyst Consensus
Rating—
Target (Mean)3.000 USD
Upside (mean)+576.6%
Target Range3.000 USD – 3.000 USD
# Analysts1
Ownership
Shares Out.33.41M
Float19.68M
Insiders1.11%
Institutions63.23%
Short Interest
Short Ratio1.3d
Short % Float0.82%
Short % Out.0.81%
Shares Short270.08K
Short (prev mo.)253.94K
Technical
SMA 500.5053 (-12.3%)
SMA 2000.6944 (-36.1%)
Beta0.34
S&P 52W Chg16.45%
Avg Vol (30d)167.92K
Avg Vol (10d)98.79K
Technical Indicators
RSI (14)33.2
MACD-0.0172
MACD Signal-0.0088
MACD Hist.-0.0084
BB Upper0.5806 USD
BB Middle0.5048 USD
BB Lower0.4290 USD
BB Width30.04%
ATR (14)0.0352 USD
Vol Ratio (20d)0.92x